Find an expert

Dr Jonathan Davies is a chronic pain researcher working to improve how pain is understood, assessed and treated. His research focuses on pain phenotyping, precision pain care, and the psychological, physiological and contextual factors that shape pain and treatment response.

At UQ’s Centre for Innovation in Pain and Health Research, he contributes to DISCERN, an NHMRC Synergy-funded multidisciplinary research program developing and validating new approaches to pain assessment. A major focus of his work is DECIPHER PAIN, a standardised, multimodal tool designed to characterise the relative contributions of nociceptive, neuropathic and nociplastic pain and support more personalised care.

His research integrates clinical assessment, quantitative sensory testing, experimental pain methods, psychophysiology, digital health and population data. He is particularly interested in how physiological signals, behaviour, language, psychosocial context and real-world health data can be combined to better understand individual differences in pain and treatment outcomes.

His broader expertise includes placebo and nocebo effects, mindfulness, mental health, quality of life, health outcome measurement and population health. His work aims to support more precise, scalable and patient-centred approaches to pain research and care.

Prof Nestor joined the Queensland Brain Institute in October/2017 and has a conjoint appointment as a cognitive neurologist at Mater Misericordiae Ltd (Mater Hospital).

His particular interests include understanding the earliest stages of Alzheimer's disease (i.e. before dementia is established); atypical forms of dementia with a particular focus on primary progressive aphasia and dementias related to Parkinson's and Lewy body diseases; and improving differential diagnosis between the major categories of neurodegenerative diseases.

He works on development of neuropsychological tests of cognition, both to accurately track change over time and improve diagnostic accuracy between the major diseases causing dementia. He also uses multi-modal imaging (magnetic resonance imaging [MRI] and positron emission tomography [PET]) to understand the sequence of events occurring in degenerative brain diseases (particularly Alzheimer's disease, frontotemporal dementia, Parkinson's disease, motor neuron disease [ALS], progressive supranuclear palsy [PSP] and corticobasal degeneration [CBD]) and identify novel biomarkers. A major focus of his is on developing novel approaches to MR imaging for single subject pathological diagnoses that can be exported into the everyday clinical setting; recent examples include diffusion tensor imaging to identify PSP and CBD (Sajjadi et al, 2013) and quantitative susceptibility mapping in Parkinson's disease (Acosta-Cabornero et al, 2013).